The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
暂无分享,去创建一个
M Jeffreys | P Thokala | J Peters | T Moxham | P. Thokala | A. Wailoo | A. Miners | J. Peters | C. Hyde | M. Hoyle | G. Rogers | M. Bond | T. Moxham | C Hyde | M Bond | G Rogers | R Anderson | M Hoyle | A Miners | S Davis | A Wailoo | R. Anderson | S. Davis | M. Jeffreys
[1] M. Knapp,et al. Costs and cognitive disability: modelling the underlying associations , 2002, British Journal of Psychiatry.
[2] F. Verhey,et al. A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia , 2005, International Psychogeriatrics.
[3] E. Aguglia,et al. Stress in the caregivers of Alzheimer's patients: An experimental investigation in ltaly , 2004, American journal of Alzheimer's disease and other dementias.
[4] A Whitehead,et al. Borrowing strength from external trials in a meta-analysis. , 1996, Statistics in medicine.
[5] J Huff,et al. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. , 1997, Alzheimer disease and associated disorders.
[6] M. Aalabaf-Sabaghi. Decision modelling for health economic evaluation , 2007, Journal of Epidemiology and Community Health.
[7] C. Wild. [Drug treatments for Alzheimer's disease] , 2001 .
[8] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[9] B. Winblad,et al. An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial , 2002, Dementia and Geriatric Cognitive Disorders.
[10] Pierre N Tariot,et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.
[11] B. Winblad,et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule , 2007, International journal of geriatric psychiatry.
[12] M. Pitt,et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. , 2012, Health technology assessment.
[13] Timo Grimmer,et al. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[14] D. Bennett,et al. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease , 2005, Journal of the International Neuropsychological Society.
[15] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[16] G. Wilcock,et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.
[17] N. Tarrier,et al. The impact of the Symptoms of dementia on caregivers , 1997, British Journal of Psychiatry.
[18] T. Asada. Prevention of Alzheimer’s disease: Putative nutritive factors , 2007 .
[19] E M Frank,et al. Effect of Alzheimer's disease on communication function. , 1994, Journal of the South Carolina Medical Association.
[20] I. Olkin,et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.
[21] C. Guilleminault,et al. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. , 2008, Chest.
[22] Steven G Potkin,et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[23] G. Livingston,et al. Depression and other psychiatric morbidity in carers of elderly people living at home , 1996, BMJ.
[24] K. Andersen,et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia , 2004, Health and quality of life outcomes.
[25] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[26] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[27] P. Raina,et al. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.
[28] R. Bullock. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings , 2005, Current medical research and opinion.
[29] D. Wilkinson,et al. Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease , 2001, International journal of geriatric psychiatry.
[30] Hee-Yeon Jung,et al. Economic and Clinical Benefits of Galantamine in the Treatment of Mild to Moderate Alzheimer's Disease in a Korean Population: A 52-Week Prospective Study , 2008, Journal of Korean medical science.
[31] L. Bäckman,et al. Multiple cognitive deficits during the transition to Alzheimer's disease , 2004, Journal of internal medicine.
[32] T. Tombaugh. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. , 2005, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.
[33] G. Walstra,et al. Determinants of Global Clinical Change Assessment in Patients with Early Alzheimer’s Disease , 1998, Dementia and Geriatric Cognitive Disorders.
[34] A. Gray,et al. Estimating the relationship between disease progression and cost of care in dementia , 2002, British Journal of Psychiatry.
[35] Oscar L. Lopez,et al. Survival following dementia onset: Alzheimer's disease and vascular dementia , 2005, Journal of the Neurological Sciences.
[36] Henry Brodaty,et al. Psychosocial Effects on Carers of Living with Persons with Dementia , 1990, The Australian and New Zealand journal of psychiatry.
[37] J. Mintzer,et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial , 2001, Journal of neurology, neurosurgery, and psychiatry.
[38] J. Elston,et al. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. , 2009, Health technology assessment.
[39] S. Sharp,et al. Explaining heterogeneity in meta-analysis: a comparison of methods. , 1997, Statistics in medicine.
[40] S. Kitamura. [Prognosis in Alzheimer's disease]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.
[41] Y. Agid,et al. EFFICACY AND TOLERABILITY OF RIVASTIGMINE IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER TYPE , 1998 .
[42] B. Seltzer,et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. , 2004, Archives of neurology.
[43] J. Olin,et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. , 2008, Current Alzheimer research.
[44] B. Rive,et al. Cost-Effectiveness of Memantine Compared with Standard Care in Moderate-to-Severe Alzheimer Disease in Canada , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[45] T. Erkinjuntti,et al. Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine , 2003, Dementia and Geriatric Cognitive Disorders.
[46] Bruno Vellas,et al. Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden , 2003, Journal of the American Geriatrics Society.
[47] E. Cumbo. Differential effects of rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial , 2005 .
[48] Sandra E. Black,et al. Utility-based Quality of Life Measures in Alzheimer’s Disease , 2006, Quality of Life Research.
[49] M. Oscar-Berman,et al. Memory deficits in Alzheimer's patients: A comprehensive review , 1992, Neuropsychology Review.
[50] W. G. Cochran. The combination of estimates from different experiments. , 1954 .
[51] J. Karlawish,et al. The Relationship Between Caregivers' Global Ratings of Alzheimer's Disease Patients' Quality of Life, Disease Severity, and the Caregiving Experience , 2001, Journal of the American Geriatrics Society.
[52] G. Gharabawi,et al. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®) , 1999, European journal of neurology.
[53] J. Garity. Caring for a family member with Alzheimer's disease: coping with caregiver burden post-nursing home placement. , 2006, Journal of gerontological nursing.
[54] L. Jönsson. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. , 2005, The American journal of geriatric pharmacotherapy.
[55] A Hofman,et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. , 1998, Human molecular genetics.
[56] L. Schneider,et al. Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? , 2007, Current Alzheimer research.
[57] C. Mcgilchrist,et al. Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors. , 1993, Archives of neurology.
[58] R. Sperling,et al. Donepezil therapy in clinical practice: a randomized crossover study. , 2000, Archives of neurology.
[59] A E Ades,et al. A chain of evidence with mixed comparisons: models for multi‐parameter synthesis and consistency of evidence , 2003, Statistics in medicine.
[60] A. Wimo,et al. Predictive validity of factors influencing the institutionalization of elderly people with psycho-geriatric disorders. , 1992, Scandinavian journal of primary health care.
[61] P. Tariot,et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.
[62] M. Weinstein,et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. , 1999, Medical care.
[63] T. Patterson,et al. Validity of the Quality of Well-Being Scale for Patients with Alzheimer's Disease , 1998, Journal of aging and health.
[64] C. Green. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. , 2007, PharmacoEconomics.
[65] C. Holmes,et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease , 2004, Neurology.
[66] M. Oremus. Systematic review of economic evaluations of Alzheimer’s disease medications , 2008, Expert review of pharmacoeconomics & outcomes research.
[67] F. Antoñanzas,et al. Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain , 2006, The European Journal of Health Economics.
[68] J. Karlawish,et al. Caregivers' assessments of preference-based quality of life in Alzheimer's disease , 2008, Alzheimer's & Dementia.
[69] H. Feldman,et al. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[70] H. Feldman,et al. Functional, Cognitive and Behavioral Effects of Donepezil in Patients with Moderate Alzheimer's Disease , 2002, Current medical research and opinion.
[71] G. Livingston,et al. Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer's disease in the U.K. , 2006, International Psychogeriatrics.
[72] S. Fay,et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial , 2006, Canadian Medical Association Journal.
[73] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[74] G. Waldemar,et al. Patient versus informant reported quality of life in the earliest phases of Alzheimer's disease , 2006, International journal of geriatric psychiatry.
[75] J. Hardy. New insights into the genetics of Alzheimer's disease. , 1996, Annals of medicine.
[76] Shuu‐Jiun Wang,et al. Cost‐effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan , 2008, International journal of geriatric psychiatry.
[77] W. Stalman,et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease , 2005, Neurology.
[78] R Garside,et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. , 2009, Health technology assessment.
[79] Roy W Jones,et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT , 2009, Trials.
[80] G. Lu,et al. Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.
[81] A. Mann,et al. Factors determining interrater agreement with rating global change in dementia: The cibic‐plus , 1995 .
[82] G. Oster,et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil* , 2007, Current medical research and opinion.
[83] B. Rive,et al. PND25 COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY , 2009 .
[84] M. Pittler. Systematic Reviews in Health Care: Meta‐analysis in Context , 2010 .
[85] L. Morris,et al. Factors Affecting the Emotional Wellbeing of the Caregivers of Dementia Sufferers , 1988, British Journal of Psychiatry.
[86] M. Albert,et al. Assessing patient dependence in Alzheimer's disease. , 1994, Journal of gerontology.
[87] R. Bullock,et al. A MULTINATIONAL, RANDOMISED, 12‐WEEK, COMPARATIVE STUDY OF DONEPEZIL AND RIVASTIGMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE , 2002, International journal of clinical practice.
[88] S. Bakchine,et al. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. , 2008, Journal of Alzheimer's disease : JAD.
[89] G. Schellenberg,et al. APP717, APP693, and PRIP gene mutations are rare in Alzheimer disease. , 1991, American journal of human genetics.
[90] Kristine Yaffe,et al. What explains differences between dementia patients' and their caregivers' ratings of patients' quality of life? , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[91] U. Chaikledkaew,et al. PNL2 THE COST-EFFECTIVENESS OF DONEPEZILAND RIVASTIGMINE IN THE TREATMENT OF ALZHEIMER'S DISEASE IN THAILAND PRIVATE HOSPITAL , 2005 .
[92] Robert Anderson,et al. Preventing unintentional injuries to children in the home: a systematic review of the effectiveness of programmes supplying and/or installing home safety equipment. , 2011, Health promotion international.
[93] L. Jönsson,et al. PND22 COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMER'S DISEASE IN SWEDEN , 2009 .
[94] H. Hampel,et al. Assessing Therapeutic Efficacy in a Progressive Disease , 2006, CNS drugs.
[95] Xin Yu,et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.
[96] Denis Getsios,et al. Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease , 2012, PharmacoEconomics.
[97] J. Touchon,et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period , 2005, Current medical research and opinion.
[98] M. Hoyle,et al. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. , 2009, Health technology assessment.
[99] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.
[100] P. Mecocci,et al. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post‐hoc analyses of ADAS‐cog and SIB total and single‐item scores from six randomized, double‐blind, placebo‐controlled studies , 2009, International journal of geriatric psychiatry.
[101] G. Livingston,et al. PNL1 EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV MODEL ESTIMATING THE COST EFFECTIVENESS OF MEMANTINE VERSUS STANDARD CARE IN ALZHEIMER DISEASE FROM A UK PERSPECTIVE , 2005 .
[102] F. Huppert,et al. CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia , 1986, British Journal of Psychiatry.
[103] T. Mills,et al. Measuring Health: A Guide to Rating Scales and Questionnaires , 2006 .
[104] Afshin Borhani Haghighi,et al. Does Serotonin Augmentation Have Any Effect on Cognition and Activities of Daily Living in Alzheimer's Dementia?: A Double-Blind, Placebo-Controlled Clinical Trial , 2007, Journal of clinical psychopharmacology.
[105] C. Brayne,et al. Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. , 2006, Age and ageing.
[106] R. Mohs,et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.
[107] T Moxham,et al. The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model. , 2009, Health technology assessment.
[108] P. Tariot,et al. A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease , 2007, Alzheimer disease and associated disorders.
[109] K. Davis,et al. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. , 1983, Psychopharmacology bulletin.
[110] T. H. Blau. Quality of life, social indicators, and criteria of change. , 1977 .
[111] Jenny Berg,et al. Health utilities in mild cognitive impairment and dementia: a population study in Sweden , 2007, International journal of geriatric psychiatry.
[112] D. Roth,et al. Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease , 2006, Neurology.
[113] Christian Guilleminault,et al. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. , 2006, Sleep.
[114] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.
[115] Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents. , 2001, Archives of gerontology and geriatrics. Supplement.
[116] Martin Hoyle,et al. Whose Costs and Benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient Cohorts , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[117] G. Suh. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[118] S. Ancoli-Israel,et al. Effects of Galantamine Versus Donepezil on Sleep in Patients With Mild to Moderate Alzheimer Disease and Their Caregivers: A Double-Blind, Head-to-Head, Randomized Pilot Study , 2005, Alzheimer disease and associated disorders.
[119] P. Phillips,et al. Psychophysiological mediators of caregiver stress and differential cognitive decline. , 2005, Psychology and aging.
[120] J. Corey-Bloom,et al. Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.
[121] L. Schneider,et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. , 2004, The American journal of psychiatry.
[122] Sube Banerjee,et al. EUROCARE: a cross‐national study of co‐resident spouse carers for people with Alzheimer's disease: I—factors associated with carer burden , 1999, International journal of geriatric psychiatry.
[123] M. Pitt,et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. , 2008, Health technology assessment.
[124] Joy Adamson,et al. Systematic review of information and support interventions for caregivers of people with dementia , 2007, BMC geriatrics.
[125] W. Quentin,et al. Cost‐of‐illness studies of dementia: a systematic review focusing on stage dependency of costs , 2010, Acta psychiatrica Scandinavica.
[126] M. Jegermalm. Support for Carers of Older People: The Roles of the Public and Voluntary Sectors in Sweden , 2003 .
[127] J. Thompson Coon,et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. , 2010, Health technology assessment.
[128] H.-J. Möller,et al. The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1 , 1999, Dementia and Geriatric Cognitive Disorders.
[129] E. Souêtre,et al. Economic impact of Alzheimer's disease in the United Kingdom , 1999, British Journal of Psychiatry.
[130] L. Friedhoff,et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .
[131] L. Wilkins. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.
[132] C. Ballard,et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. , 2008, The Journal of clinical psychiatry.
[133] M. Oremus,et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. , 2002, Clinical therapeutics.
[134] David L. Weimer,et al. Early identification and treatment of Alzheimer's disease: Social and fiscal outcomes , 2009, Alzheimer's & Dementia.
[135] G. Livingston,et al. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care – the LASER-AD Study , 2004, Current medical research and opinion.
[136] P. Bria,et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study , 2006, European journal of neurology.
[137] D. Hosford,et al. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.
[138] D. Getsios,et al. PND10 COST-EFFECTIVENESS STUDY IN PATIENTS WITH MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE: PROJECTED BENEFITS OF DONEPEZIL IN THE UNITED KINGDOM , 2009 .
[139] Y. Agid,et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .
[140] R. Mohs,et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.
[141] S. Fay,et al. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. , 2007, Neurology.
[142] C. Brayne,et al. The Incidence of Dementia in England and Wales: Findings from the Five Identical Sites of the MRC CFA Study , 2005, PLoS medicine.
[143] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[144] B. Winblad,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.
[145] Joseph M. Currier,et al. Outcomes from the Resources for Enhancing Alzheimer's Caregiver Health (REACH) program for bereaved caregivers. , 2009, Psychology and aging.
[146] K. Lohr,et al. Functional Outcomes of Drug Treatment in Alzheimer’s Disease , 2007, Drugs & aging.
[147] Robert Blizard,et al. Prediction of survival in Alzheimer's disease—The LASER‐AD longitudinal study , 2009, International journal of geriatric psychiatry.
[148] A. Mann,et al. Predictors of institutionalisation in people with dementia , 2003, Journal of neurology, neurosurgery, and psychiatry.
[149] S. Sanders,et al. Alzheimer’s Caregiver Differences in Experience of Loss, Grief Reactions and Depressive Symptoms Across Stage of Disease , 2004 .
[150] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[151] Serge Gauthier,et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial , 2002, The Lancet.
[152] L. Weng,et al. Determinants of the discrepancy in patient- and caregiver-rated quality of life for persons with dementia. , 2009, Journal of clinical nursing.
[153] J. Raftery,et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.
[154] O. Almkvist,et al. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease , 2003, Acta neurologica Scandinavica. Supplementum.
[155] H. D. de Vet,et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria , 2005, International Journal of Technology Assessment in Health Care.
[156] L. Schneider,et al. Sociodemographic and clinical correlates of utility scores in Alzheimer's disease. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[157] H. Soininen,et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. , 2009, Current Alzheimer research.
[158] S. Gauthier,et al. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis , 2008, International journal of geriatric psychiatry.
[159] H. Fillit,et al. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. , 2005, The American journal of geriatric pharmacotherapy.
[160] Bruno Vellas,et al. Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease , 2002, International Psychogeriatrics.
[161] D. Iglehart. Simulating stable stochastic systems, V: Comparison of ratio estimators , 1975 .
[162] M Knapp,et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. , 2005, Health technology assessment.
[163] Roy W Jones,et al. A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease , 2004, International journal of geriatric psychiatry.
[164] K. Stein,et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. , 2007, Health technology assessment.
[165] A. Wimo,et al. The Cost of Dementia in Europe A Review of the Evidence , and Methodological Considerations , 2009 .
[166] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[167] G. Frisoni,et al. Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit. , 1995, Dementia.
[168] Brian Hutton,et al. Does analysis using “last observation carried forward” introduce bias in dementia research? , 2008, Canadian Medical Association Journal.
[169] H. Meltzer,et al. The prevalence of disability among adults , 1988 .
[170] Giovanni Defazio,et al. Rate of MMSE score change in Alzheimer's disease: Influence of education and vascular risk factors , 2009, Clinical Neurology and Neurosurgery.
[171] B. Winblad,et al. An active and socially integrated lifestyle in late life might protect against dementia , 2004, The Lancet Neurology.
[172] M. Hoyle. Future Drug Prices and Cost-Effectiveness Analyses , 2012, PharmacoEconomics.
[173] M. Farlow,et al. Memantine for the Treatment of Alzheimer’s Disease , 2008, Drug safety.
[174] Bruno Vellas,et al. Exercise Program for Nursing Home Residents with Alzheimer's Disease: A 1‐Year Randomized, Controlled Trial , 2007, Journal of the American Geriatrics Society.
[175] M. Albert,et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. , 1997, JAMA.
[176] M Knapp,et al. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding , 2001, International journal of geriatric psychiatry.
[177] A. Comas-Herrera,et al. Cognitive impairment in older people: future demand for long‐term care services and the associated costs , 2007, International journal of geriatric psychiatry.
[178] D. Getsios,et al. PND11 COST-EFFECTIVENESS OF SCREENING AND TREATMENT OF ALZHEIMER'S DISEASE WITH DONEPEZIL IN THE UNITED KINGDOM , 2009 .
[179] Gunhild Waldemar,et al. Patient- and Proxy-Reported Utility in Alzheimer Disease Using the EuroQoL , 2006, Alzheimer disease and associated disorders.